Patents by Inventor Mathew G. Miller

Mathew G. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED DNA POLYMERASE VARIANTS
    Publication number: 20230193224
    Abstract: The present disclosure relates to engineered DNA polymerase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered DNA polymerase polypeptides. The present disclosure also provides methods of using the engineered DNA polymerase polypeptides or compositions thereof for diagnostic and other purposes.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 22, 2023
    Inventors: Ericka Bermudez, David Elgart, Nikki D. Kruse, Mathew G. Miller, Vesna Mitchell, Jovana Nazor, Nandhitha Subramanian
  • RECOMBINANT REVERSE TRANSCRIPTASE VARIANTS
    Publication number: 20230183790
    Abstract: The present disclosure relates to recombinant reverse transcriptase polypeptides and compositions thereof, as well as polynucleotides encoding the recombinant reverse transcriptase polypeptides. The disclosure also provides methods for using the recombinant reverse transcriptase polypeptides and compositions thereof for diagnostic and as molecular biological tools.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 15, 2023
    Inventors: Ericka Bermudez, David Elgart, Mathew G. Miller, Jovana Nazor, Zhe Rui, Nandhitha Subramanian
  • ENGINEERED TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE VARIANTS
    Publication number: 20230183663
    Abstract: The present invention provides engineered terminal deoxynucleotidyl transferase (TdT) polypeptides useful in template-independent polynucleotide synthesis using a nucleoside triphosphate-3?-O-removable blocking group (NTP-3?-O-RBG), as well as compositions, methods of utilizing these engineered polypeptides, and polynucleotides encoding the engineered terminal deoxynucleotidyl transferases.
    Type: Application
    Filed: October 13, 2022
    Publication date: June 15, 2023
    Inventors: Charlene Ching, Stephanie Marie Forget, Anders Matthew Knight, Mikayla Jianghongxia Krawczyk, Niusha Mahmoodi, Melissa Ann Mayo, Mathew G. Miller, Jonathan Vroom
  • Human alpha-galactosidase variants
    Patent number: 11497798
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: November 15, 2022
    Assignee: Codexis, Inc.
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • T7 RNA POLYMERASE VARIANTS
    Publication number: 20220186197
    Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 16, 2022
    Inventors: Mathew G. Miller, Chinping Chng, Oscar Alvizo, Melissa Ann Mayo, James Nicholas Riggins, Xiang Yi, Jonathan S. Penfield, Gjalt W. Huisman, Jared Davis, Yasushi Saotome
  • Human alpha-galactosidase variants
    Patent number: 11278600
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: March 22, 2022
    Assignee: Codexis, Inc.
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • T7 RNA polymerase variants
    Patent number: 11236311
    Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: February 1, 2022
    Assignee: Codexis, Inc.
    Inventors: Mathew G. Miller, Chinping Chng, Oscar Alvizo, Melissa Ann Mayo, James Nicholas Riggins, Xiang Yi, Jonathan S. Penfield, Gjalt W. Huisman, Jared Davis, Yasushi Saotome
  • T7 RNA polymerase variants
    Patent number: 11236312
    Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: February 1, 2022
    Assignee: Codexis, Inc.
    Inventors: Mathew G. Miller, Chinping Chng, Oscar Alvizo, Melissa Ann Mayo, James Nicholas Riggins, Xiang Yi, Jonathan S. Penfield, Gjalt W. Huisman, Jared Davis, Yasushi Saotome
  • ENGINEERED DNA POLYMERASE VARIANTS
    Publication number: 20210309977
    Abstract: The present invention provides engineered DNA polymerase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered DNA polymerase polypeptides. The invention also provides methods for use of the compositions comprising the engineered DNA polymerase polypeptides for diagnostic and other purposes.
    Type: Application
    Filed: June 11, 2021
    Publication date: October 7, 2021
    Inventors: Mathew G. Miller, Vesna Mitchell, Jovana Nazor, Donald S. Baskerville, Nikki Dellas, David Elgart, Jonathan Vroom, Sandy M. Gomes, Nandhitha Subramanian, Ericka Bermudez
  • HUMAN ALPHA-GALACTOSIDASE VARIANTS
    Publication number: 20210244804
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Application
    Filed: March 9, 2021
    Publication date: August 12, 2021
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • Engineered DNA polymerase variants
    Patent number: 11060075
    Abstract: The present invention provides engineered DNA polymerase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered DNA polymerase polypeptides. The invention also provides methods for use of the compositions comprising the engineered DNA polymerase polypeptides for diagnostic and other purposes.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: July 13, 2021
    Assignee: Codexis, Inc.
    Inventors: Mathew G. Miller, Vesna Mitchell, Jovana Nazor, Donald S. Baskerville, Nikki Dellas, David Elgart, Jonathan Vroom, Sandy M. Gomes, Nandhitha Subramanian, Ericka Bermudez
  • Human alpha-galactosidase variants
    Patent number: 10973888
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: April 13, 2021
    Assignee: Codexis, Inc.
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • HUMAN ALPHA-GALACTOSIDASE VARIANTS
    Publication number: 20200405826
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH <4.5) and basic (pH >7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Application
    Filed: August 5, 2020
    Publication date: December 31, 2020
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • HUMAN ALPHA-GALACTOSIDASE VARIANTS
    Publication number: 20200360489
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH <4.5) and basic (pH >7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Application
    Filed: August 5, 2020
    Publication date: November 19, 2020
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • HUMAN ALPHA-GALACTOSIDASE VARIANTS
    Publication number: 20200360490
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Application
    Filed: August 5, 2020
    Publication date: November 19, 2020
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • T7 RNA POLYMERASE VARIANTS
    Publication number: 20200354699
    Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
    Type: Application
    Filed: July 29, 2020
    Publication date: November 12, 2020
    Inventors: Mathew G. Miller, Chinping Chng, Oscar Alvizo, Melissa Ann Mayo, James Nicholas Riggins, Xiang Yi, Jonathan S. Penfield, Gjalt W. Huisman, Jared Davis, Yasushi Saotome
  • T7 RNA POLYMERASE VARIANTS
    Publication number: 20200354698
    Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
    Type: Application
    Filed: July 24, 2020
    Publication date: November 12, 2020
    Inventors: Mathew G. Miller, Chinping Chng, Oscar Alvizo, Melissa Ann Mayo, James Nicholas Riggins, Xiang Yi, Jonathan S. Penfield, Gjalt W. Huisman, Jared Davis, Yasushi Saotome
  • T7 RNA polymerase variants
    Patent number: 10793841
    Abstract: The present invention provides engineered T7 RNA polymerase variants and compositions thereof. These variants have been evolved for selective incorporation of the symmetrical capped GTP analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for using the variants provided herein. The present invention further provides for the use of the compositions provided herein.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: October 6, 2020
    Assignee: Codexis, Inc.
    Inventors: Mathew G. Miller, Chinping Chng, Oscar Alvizo, Melissa Ann Mayo, James Nicholas Riggins, Xiang Yi, Jonathan S. Penfield, Gjalt W. Huisman
  • T7 RNA polymerase variants
    Patent number: 10738286
    Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: August 11, 2020
    Assignee: Codexis, Inc.
    Inventors: Mathew G. Miller, Chinping Chng, Oscar Alvizo, Melissa Ann Mayo, James Nicholas Riggins, Xiang Yi, Jonathan S. Penfield, Gjalt W. Huisman, Jared Davis, Yasushi Saotome
  • ENGINEERED DNA POLYMERASE VARIANTS
    Publication number: 20200131485
    Abstract: The present invention provides engineered DNA polymerase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered DNA polymerase polypeptides. The invention also provides methods for use of the compositions comprising the engineered DNA polymerase polypeptides for diagnostic and other purposes.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 30, 2020
    Inventors: Mathew G. Miller, Vesna Mitchell, Jovana Nazor, Donald S. Baskerville, Nikki Dellas, David Elgart, Jonathan Vroom, Sandy M. Gomes, Nandhitha Subramanian, Ericka Bermudez